Parsons James T. - 02 Jan 2026 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
06 Jan 2026, 17:24:34 UTC
Prior SEC filing
02 Jan 2026
Next SEC filing
13 Mar 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Scott Kellen, attorney-in-fact

Key filing fact

Parsons James T. filed Form 4 for DiaMedica Therapeutics Inc. (DMAC) on 06 Jan 2026.

Key facts

  • This page summarizes Parsons James T.'s Form 4 filing for DiaMedica Therapeutics Inc. (DMAC).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 06 Jan 2026, 17:24.

Change

  • Previous filing in this sequence was filed on 02 Jan 2026.
  • Current net transaction value: +$85,000.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001759855 Primary reporting owner

Parsons James T.

Relationship
Director
Address
301 CARLSON PARKWAY, SUITE 210, MINNEAPOLIS
Signature
/s/ Scott Kellen, attorney-in-fact
Signature date
06 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DMAC transaction

Common Stock

Award

Transaction value
$85,000
Shares
+10,095
Change %
+11%
Price
$8.42
Shares after
97,949
Date
02 Jan 2026
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Shares are issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan, in lieu of cash retainer fees in the aggregate amount of $85,000. The deferred stock units are scheduled to vest in four nearly equal installments on each of March 31, June 30, September 30, and December 31, 2026.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .